Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01835626 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
A Phase 2 study of Skin Cancer and Locally Advanced Basal Cell Carcinoma, sponsored by Sue Yom.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT01835626: Completed Phase 2 study of Skin Cancer and Locally Advanced Basal Cell Carcinoma, sponsored by Sue Yom.
NCT01835626 is a Phase 2 study of Skin Cancer and Locally Advanced Basal Cell Carcinoma that has completed, run by Sue Yom. The registered enrollment target is 24 participants, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01835626, a Phase 2 study of Skin Cancer and Locally Advanced Basal Cell Carcinoma, has completed, sponsored by Sue Yom.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
Chemotherapy, radiation therapy, and surgery are standard treatments for basal cell carcinoma at most institutions. The purpose of this study is to determine whether adding vismodegib to radiation (chemoradiotherapy) is safe and tolerable. The purpose of this study is to assess the safety and tolerability of combined radiation therapy and vismodegib. This combination may increase the chances of the tumors being destroyed or unable to spread to other parts of the body in people with locally advanced basal cell carcinoma of the head and neck.
Primary Outcome
The local-regional control rate at 12 months from protocol therapy completion, defined as absence of progressive disease within the irradiated planning tumor volumes (PTV) for patients with locally advanced basal cell carcinoma in the head and neck.
Conditions Studied
Interventions
- DRUG Vismodegib
- RADIATION Radiation therapy
Study Locations (2)
California
- University of California, San Francisco - San Francisco
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-05 |
| Est. Completion | 2019-09-10 |
| Phase | Phase 2 |
What the finished NCT01835626 record still lists
NCT01835626 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Skin Cancer appearing as the primary indexed condition, and to 2 interventions - of which Vismodegib is the first listed.
NCT01835626 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT01835626 about?
NCT01835626 is a clinical study titled "Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma". Chemotherapy, radiation therapy, and surgery are standard treatments for basal cell carcinoma at most institutions. The purpose of this study is to determine whether adding vismodegib to radiation (chemoradiotherapy) is safe and tolerable. The purpose of this study is to assess the safety and tolera...
What is the current status of trial NCT01835626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2013-05. Estimated completion is 2019-09-10.
What conditions does trial NCT01835626 study?
This clinical trial studies the following conditions: Skin Cancer, Locally Advanced Basal Cell Carcinoma, Cutaneous Malignancy.
What interventions are being tested in trial NCT01835626?
The interventions under investigation include: Vismodegib (DRUG), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01835626?
This trial is sponsored by Sue Yom, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01835626 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01835626's enrollment target sits among peer trials
24 36th of 40 higher than 5 of 40 other Skin Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RECRUITING · Phase 2
-
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Study of Talabostat and Cisplatin in Advanced Melanoma
COMPLETED · Phase 2
-
Phase II Trial of Allovectin-7® for Metastatic Melanoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia